Since normal prostate tissue as well as benign prostate tumors are mostly GRPR-negative, this receptor emerged as an attractive target for new diagnostic approaches and radionuclide therapeutic applications for PC patients [2]. This evidence concerns the gene GRPR and pachyonychia congenita.